Watching our co-ops grow and excel during their time at Entrada has been a privilege. Their hard work and dedication have left a lasting impact, and we’re excited to see all they will accomplish in the future. Please join us in celebrating the contributions of this talented group. Always remember, once an Entradan, always an Entradan! Learn more about what it's like to work with us: https://lnkd.in/eMt4CsU #EntradaHere #Hiring #CoOp
Entrada Therapeutics
Biotechnology Research
Boston, MA 25,544 followers
Innovating to transform the treatment of devastating diseases through intracellular therapeutics.
About us
Headquartered in Boston’s Seaport community, Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. Our Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of active moieties into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, we are advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. Our lead oligonucleotide programs are in development for the treatment of people living with Duchenne muscular dystrophy who are exon 44, 45 and 50 skipping amenable. Entrada has partnered VX-670, a clinical-stage program for the treatment of myotonic dystrophy type 1. For more information about Entrada, please visit our website, www.entradatx.com
- Website
-
https://www.entradatx.com/
External link for Entrada Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
One Design Center
Boston, MA 02210, US
Employees at Entrada Therapeutics
Updates
-
Dipal Doshi, Entrada’s Chief Executive Officer, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. Pacific Time in San Francisco, California. Register for the webcast here: https://lnkd.in/ehcPuS3d #InvestorRelations #Biotech
-
#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape
-
Last Monday, we were honored to welcome the Dreher family to our office — who live with Duchenne muscular dystrophy and founded the NH-based Duchenne nonprofit Hope for Gus. During their visit, we toured the labs while taking photos with Gus, and later had the opportunity to hear about both their lived experience and the work they’re doing to improve experiences of Duchenne families here and in Nepal. A big thank you to the Dreher family for joining us! Enjoy some of our favorite memories from the day. To learn more about Hope for Gus and their work in Nepal, please visit: https://hopeforgus.org/ #DMD #Duchenne #EntradaHere
-
As the year comes to a close, it's a great time to revisit the research supporting our growing pipeline. We publish our research with high ethical standards, adhering to recognized industry guidance. Explore our presentations: https://lnkd.in/ed8345DB #Biotech #Research
-
#ICYMI: We are incredibly proud to have received one of Boston Globe Media’s DEI Champion awards, as part of their Top Places to Work program. This would not have been possible without our amazing partners: Boston While Black, Latinos in Bio, OUTbio and WIB-Greater Boston. We look forward to working with them again next year to raise the bar at Entrada and across our industry! Read more about our approach to CSR: https://lnkd.in/eeKCzbE2 #Biotech #CSR #DEI
-
Nathan Dowden, Entrada’s President and Chief Operating Officer, and Natarajan Sethuraman, PhD, President of Research and Development, participated in a fireside chat alongside Jonathan Miller, Managing Director of Biotech Equity Research at Evercore, during the 7th Annual Evercore HealthCONx Conference. A replay of the fireside chat is available here: https://lnkd.in/e6_UBk-n #InvestorRelations #Biotech
-
Once again, we are pleased to share that Entrada has been recognized as a Top Place to Work and a DEI Champion by Boston Globe Media! Our mission to treat devastating diseases with intracellular therapeutics is at the forefront of everything we do, driving us to push boundaries and redefine possibilities. A huge thank you to our incredible team for making Entrada a Top Place to Work! Discover why Entrada stands out and consider joining us! https://lnkd.in/dnAADxwi #TopPlacesToWork #BostonGlobe #EntradaHere
-
This Thanksgiving, we are so thankful for our Entrada team and broader community. Together, we are working to help patients and their families live better lives. Have a safe and happy Thanksgiving weekend! #Thanksgiving2024 #EntradaHere #Biotech
-
Last Thursday, we had the honor of attending the 2nd Latinos in Bio Annual Gala in Boston, MA! The evening was truly special, featuring an inspiring awards dinner, networking opportunities and an unforgettable night on the dance floor. We’re proud to celebrate the achievements and contributions of the Latino community in the biotech and life sciences industries. Thank you, Carolina Alarco, Jose Estabil and the Latinos in Bio organizing committee for hosting such an incredible event! Interested in joining our team? Explore our careers page today: https://lnkd.in/eXjmC27B #LatinosInBio #Networking #CelebratingDiversity